Send to

Choose Destination

Links from PubMed

Oncoimmunology. 2013 Jun 1;2(6):e24500. Epub 2013 Apr 16.

Strategies for purging CD96+ stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia.

Author information

Division of Stem Cell Transplantation and Immunotherapy; 2nd Department of Medicine; Christian-Albrechts-University of Kiel; Kiel, Germany.


The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+ AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologous hematopoietic progenitor cell transplantation.


CD96; acute myeloid leukemia; graft engineering; leukemic stem cells; purging; targeted therapy

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center